scispace - formally typeset
A

Alan Ashworth

Researcher at University of California, San Francisco

Publications -  589
Citations -  82138

Alan Ashworth is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 134, co-authored 578 publications receiving 72089 citations. Previous affiliations of Alan Ashworth include Imperial College London & Papworth Hospital.

Papers
More filters
Journal ArticleDOI

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells

TL;DR: The combination of a NAMPT small molecule inhibitor, FK866, with olaparib inhibited TN breast tumour growth in vivo to a greater extent than either single agent alone suggesting that assessing NAMpt/PARP inhibitor combinations for the treatment of TN breast cancer may be warranted.
Journal ArticleDOI

Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus : Putative Functional Variants Differentially Bind FOXA1 and E2F1

Kerstin B. Meyer, +215 more
TL;DR: A role for FOXA1 in mediating breast cancer susceptibility at this locus is consistent with the finding that the FGFR2 risk locus primarily predisposes to estrogen-receptor-positive disease.
Journal ArticleDOI

Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation

Maya Ghoussaini, +235 more
TL;DR: Evidence suggests that the g-allele confers increased breast cancer susceptibility through relative downregulation of IGFBP5, a gene with known roles in breast cell biology, which is associated with oestrogen receptor positive (ER+) disease.
Journal ArticleDOI

Drug resistance caused by reversion mutation.

TL;DR: It is shown that this sensitivity can be reversed, and resistance to PARP inhibition can be acquired by deletion of a mutation in BRCA2, and a similar mechanism seems to be associated with carboplatin resistance in some BRCa2 mutation carriers with ovarian cancer.